Business Context and Reporting Period
This Form 8-K filing by XpresSpa Group, Inc. (trading as XSPA) reports a material definitive agreement entered into on December 17, 2020. The filing details a registered direct offering of common stock and warrants, with the transaction closing on December 21, 2020.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $41.7 million raised from the sale of securities.
- Securities Issued: 24,509,806 shares of Common Stock and warrants exercisable for an equal number of shares.
- Offering Price: $1.70 per share (combined price for share and warrant).
- Warrant Terms: Exercise price of $1.70 per share; immediately exercisable; 24-month expiration.
- Placement Agent Fees: 7.5% cash fee plus 1.0% management fee on gross proceeds, plus reimbursement of expenses and legal fees up to $40,000.
- Additional Warrants Issued:
- Placement Agent Warrants: 1,960,784 shares (8.0% of offering) at an exercise price of $2.125 (125% of offering price).
- Palladium Warrants: 754,902 shares issued to Palladium Capital Advisors, LLC.
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement for the registered direct offering. The company engaged H.C. Wainwright & Co., LLC as the placement agent. The agreement includes a "lock-up" provision where holders cannot exercise warrants if it results in ownership exceeding 4.99% (or 9.99% with notice) of outstanding common stock. Additionally, the placement agent secured a 12-month right of first refusal to act as financial advisor for mergers or as the sole underwriter for future debt and equity financings.
Outlook, Risks, and Contingencies
The filing does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of general business risks beyond the standard legal disclaimers regarding the legality of the securities offering. The transaction is subject to the terms of the Purchase Agreement and the effectiveness of the Form S-3 registration statement (declared effective August 5, 2020).
Investor Verification Checklist
- Verify the final net proceeds after deducting the 8.5% total placement agent fees and other offering expenses.
- Confirm the dilution impact of the 24.5 million new shares plus the potential exercise of 24.5 million warrants and additional agent warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and redemption rights.
- Check subsequent filings for the company's cash position post-closing to assess liquidity improvements.